Company Overview of Regenxbio Inc.
REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company’s development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a p...
1701 Pennsylvania Avenue, NW
Washington, DC 20006
Founded in 2008
Key Executives for Regenxbio Inc.
Chief Executive Officer, President, Director and Member of Disclosure Committee
Chief Financial Officer, Senior Vice President of Corporate Development and Member of Disclosure Committee
Chief Medical Officer and Member of Disclosure Committee
Vice President, General Counsel, Secretary and Member of Disclosure Committee
Compensation as of Fiscal Year 2015.
Regenxbio Inc. Key Developments
REGENX Biosciences Seeks Acquisitions
Aug 17 15
Regenxbio Inc. is seeking acquisitions. REGENXBIO has filed an IPO in the amount of $100.00 million. The proceeds from the initial public offering will be used for working capital, general and administrative expenses, internal research and development expenses, manufacturing and other general corporate purposes, including in-licenses and potential acquisitions.
REGENXBIO Inc Enters into Strategic Manufacturing Collaboration with WuXi AppTec, Inc
Jun 11 15
REGENXBIO Inc. announced that it has entered into an exclusive strategic manufacturing collaboration with WuXi AppTec, Inc. Through this collaboration, REGENXBIO plans to establish efficient, scalable manufacturing processes within current Good Manufacturing Practice guidelines for the production of adeno-associated virus gene therapy treatments incorporating REGENXBIO's NAV Technology. Under the terms of the agreement, REGENXBIO and WuXi will establish a proprietary production process for NAV Technology treatments designed to enable the rapid advancement of REGENXBIO's and licensees' therapeutic programs from clinical trials through commercialization in WuXi's 145,000 square-foot cGMP facility currently under construction in Philadelphia. This facility is specially designed to accommodate gene therapy products that contain viral vectors such as REGENXBIO's NAV Technology platform. The partnership will combine REGENXBIO's expertise in AAV process development with WuXi's commercial manufacturing proficiency and established infrastructure. As part of the collaboration, REGENXBIO has already initiated with WuXi the production of material to be used in planned clinical trials. This unique collaboration enables WuXi to work closely with REGENXBIO to provide an integrated solution to its gene therapy needs.
REGENXBIO Inc. Announces Board Changes
May 27 15
REGENXBIO Inc. announced the appointment of Jerry Karabelas, Ph.D., to its board of directors. Most recently, Dr. Karabelas has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences Inc., Vanda Pharmaceuticals Inc. and SkyePharma PLC. He currently chairs the boards of Inotek and Polyphor, AG and is a partner at Care Capital. In addition, the company announced that Daniel Kiser and Michael Gelman have resigned from the board of directors.
Similar Private Companies By Industry
Recent Private Companies Transactions